ARC Group Limited is proud to announce the successful completion of a strategic divestment deal between Jiangsu Fresenius Medical Care Hospital Management Services Co., Ltd. (a subsidiary of Fresenius Medical Care) and Jiangxi Dakang Medical Management Co., Ltd. The transaction marks a significant milestone in the expansion efforts of both parties within the renal care sector in China.
Fresenius Medical Care
Fresenius Medical Care, a Fortune 500 company, commands a prominent position as a leader in offering comprehensive solutions across the dialysis value chain. With a global network spanning approximately 4,000 dialysis clinics, the company attends to over 332,000 patients worldwide. Operating around 40 production sites across all continents, Fresenius Medical Care ensures the availability of critical dialysis products such as machines, dialyzers, and related disposables.
Driven by a relentless pursuit of excellence, Fresenius Medical Care is committed to consolidating its expertise, utilizing it as a foundation for sustainable and profitable growth. The company’s primary objective is to enhance the quality of life for patients by providing high-quality products, innovative technologies, and advanced treatment concepts.
Fresenius Medical Care’s corporate headquarters are in Bad Homburg v. d. Höhe, Germany, with regional offices strategically positioned across key regions. In North America, the company operates from Waltham, Massachusetts, while in the Asia-Pacific region, its presence extends from Hong Kong. Additionally, the company’s South American regional offices are situated in Rio de Janeiro, Brazil.
Jiangxi Dakang Medical Management Co., Ltd
Jiangxi Dakang Medical Management Co., Ltd., distinguished as the foremost brand in hemodialysis services within China, stands as the inaugural brand of the former independent hemodialysis centre under the National Ministry of Health. Established in 2012, Dakang Medical emerges as a premier entity in medical investment, medical institution management, brand operation, and service provision. Currently, Dakang Medical boasts the largest constellation of hemodialysis centers across China, with over 70 independent centers either operational or under development in 15 provinces, including Jiangxi, Shandong, Hebei, Henan, Shanxi, Hubei, Anhui, Guangdong, Yunnan, Guangxi, Sichuan, Guizhou, Liaoning, among others. With its comprehensive medical resources, Dakang Medical facilitates a trend towards chain and large-scale medical institutions.
The acquisition deal facilitated by ARC Group involved the purchase of 70% equities of three prominent hospitals: Kunming Wuhua Health Hospital Co., Ltd., Ziyang Zhongxin Anorectal Hospital Co., Ltd., and Hejiang Kangcheng Nephrology Hospital Co., Ltd.
Sergio Camarero, President of ARC Group, states, “ARC Group is honoured to have played a pivotal role in bridging the gap between East and West in facilitating this strategic acquisition deal between Fresenius Medical Care and Jiangxi Dakang Medical Management Co., Ltd. This transaction exemplifies the potential for collaboration between industry leaders to address the evolving healthcare needs of patients worldwide.”
The completion of the acquisition underscores the resilience and adaptability of the parties involved in driving forward their shared vision for the future of renal care in China. ARC Group is pleased to highlight our established record of accomplishment in this transaction. Despite the obstacles presented by cultural disparities, and intricate shareholder management structures, ARC Group collaborated closely with both parties to effectively navigate the transaction. The successful conclusion of the acquisition underscores the resilience and flexibility of all involved parties in overcoming market challenges and advancing their collective vision for the future of renal care in China.
“We are immensely proud to have guided Fresenius Medical Care through this intricate transaction. My heartfelt congratulations extend to both parties for their unwavering dedication and collaborative spirit throughout. Overcoming the challenges underscores the resilience and adaptability of all involved. This successful acquisition marks a pivotal step forward in shaping the future of renal care in China, a testament to our collective vision and determination.” – Ulrik Karlsen, Vice President of M&A at ARC Group.
For more information or any questions, please contact:
Sergio Camarero
President
sergio.camarero@arc-group.com
